Cartesian Therapeutics (RNAC) Net Margin (2016 - 2025)
Historic Net Margin for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to 4318.14%.
- Cartesian Therapeutics' Net Margin fell 4416600.0% to 4318.14% in Q3 2025 from the same period last year, while for Sep 2025 it was 4620.62%, marking a year-over-year decrease of 41737600.0%. This contributed to the annual value of 198.97% for FY2024, which is 6459400.0% up from last year.
- Latest data reveals that Cartesian Therapeutics reported Net Margin of 4318.14% as of Q3 2025, which was down 4416600.0% from 4448.99% recorded in Q2 2025.
- Cartesian Therapeutics' 5-year Net Margin high stood at 4448.99% for Q2 2025, and its period low was 4318.14% during Q3 2025.
- For the 5-year period, Cartesian Therapeutics' Net Margin averaged around 295.37%, with its median value being 71.1% (2021).
- Data for Cartesian Therapeutics' Net Margin shows a peak YoY increase of 55776700bps (in 2024) and a maximum YoY decrease of -37390700bps (in 2024) over the last 5 years.
- Over the past 5 years, Cartesian Therapeutics' Net Margin (Quarter) stood at 40.88% in 2021, then decreased by -14bps to 35.09% in 2022, then tumbled by -6880bps to 2379.12% in 2023, then surged by 234bps to 3198.55% in 2024, then plummeted by -235bps to 4318.14% in 2025.
- Its last three reported values are 4318.14% in Q3 2025, 4448.99% for Q2 2025, and 1806.73% during Q1 2025.